Trials / Unknown
UnknownNCT05104216
Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPD
Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and Chronic Obstructive Pulmonary Disease
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- China National Biotec Group Company Limited · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of immunogenicity, safety and persistence of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease received the third dose of inactivated COVID-19 vaccine .
Detailed description
The subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease recruited to receive a third dose of inactivated COVID-19 vaccine. Blood samples will be collected 3 times: before the third dose of vaccinatioin，28 days and 6 months after the third dose of vaccination. Any local or systemic adverse events that occurred within 21 days after vaccination will be recorded.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Inactivated COVID-19 vaccine | receive a third dose of inactivated COVID-19 vaccine |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
- First posted
- 2021-11-02
- Last updated
- 2021-11-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05104216. Inclusion in this directory is not an endorsement.